| P50 | author | Abdullah Alsultan | Q40347087 |
| P2093 | author name string | Guohua An | |
| | Charles A Peloquin | |
| P2860 | cites work | In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis | Q28367763 |
| | Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. | Q30415746 |
| | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA | Q30427912 |
| | Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis | Q33387661 |
| | Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription | Q33912931 |
| | Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis | Q34285599 |
| | Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients | Q34729493 |
| | Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis | Q35102656 |
| | Fluoroquinolones, tuberculosis, and resistance | Q35167433 |
| | Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models | Q35201049 |
| | Therapeutic drug monitoring in the treatment of active tuberculosis | Q35487794 |
| | Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials | Q35547236 |
| | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy | Q35636012 |
| | Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 |
| | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis | Q36482760 |
| | Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis | Q36669451 |
| | Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration | Q36728704 |
| | Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana | Q37145913 |
| | Serum drug concentrations predictive of pulmonary tuberculosis outcomes | Q37213037 |
| | Limited-sampling strategies for anti-infective agents: systematic review. | Q38000241 |
| | Therapeutic drug monitoring in the treatment of tuberculosis: an update | Q38213320 |
| | Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases | Q40996427 |
| | Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system | Q41840976 |
| | Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software | Q42379470 |
| | Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response | Q42693597 |
| | Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China | Q43255199 |
| | Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis | Q44029567 |
| | Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong | Q44615132 |
| | The Rapid Development of Fluoroquinolone Resistance inM. tuberculosis | Q44653435 |
| | Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling | Q44662037 |
| | Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis | Q44849406 |
| | Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin | Q45346443 |
| | Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis | Q46272585 |
| | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis | Q46448545 |
| | Therapeutic drug monitoring in the treatment of tuberculosis patients. | Q50984506 |
| | Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. | Q51643088 |
| | Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. | Q51915286 |
| | Some suggestions for measuring predictive performance | Q52875851 |
| | Acquired Drug Resistance: We Can Do More Than We Think! | Q58033436 |
| | Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council | Q69881424 |
| | Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months | Q70193423 |
| | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS C | Q73815453 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| | levofloxacin | Q424193 |
| P304 | page(s) | 3800-3807 | |
| P577 | publication date | 2015-04-13 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis | |
| P478 | volume | 59 | |